[{"arm_notes": "", "treatment_id": null, "treatment_name": "Dosing and AdministrationAll subjects will receive remdesivir as a 200 mg intravenous (IV) loading dose on Day 1; followed by a 100 mg once-daily IV maintenance dose for the duration of the hospitalization up to a 10-day total course. If subjects already received the loading dose as under the EUA or similar mechanism; then start at 100 mg/day. Any doses of remdesivir under an EUA (or similar mechanism) prior to enrollment will be counted; so the total duration of remdesivir (i.e. EUA + on this trial) is 10 days (i.e.; a maximum of 10 total infusions). If one or two doses of remdesivir were administered (under EUA or similar mechanism) prior to study enrollment; this should be documented in eClinical as a concomitant medication given prior to Day 1.For the baricitinib component; subjects will receive either active product or placebo as follows:- Baricitinib will be administered as a 4 mg orally (po) (two 2mg tablets) or crushed for NG tube; daily for the duration of the hospitalization up to a 14-day total course.- A placebo will be given as two tablets po or crushed for NG tube; daily for the duration of the hospitalization up to a 14-day total course.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 181, "treatment_name": "Baricitinib", "treatment_type": "Kinase inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Dosing and AdministrationAll subjects will receive remdesivir as a 200 mg intravenous (IV) loading dose on Day 1; followed by a 100 mg once-daily IV maintenance dose for the duration of the hospitalization up to a 10-day total course. If subjects already received the loading dose as under the EUA or similar mechanism; then start at 100 mg/day. Any doses of remdesivir under an EUA (or similar mechanism) prior to enrollment will be counted; so the total duration of remdesivir (i.e. EUA + on this trial) is 10 days (i.e.; a maximum of 10 total infusions). If one or two doses of remdesivir were administered (under EUA or similar mechanism) prior to study enrollment; this should be documented in eClinical as a concomitant medication given prior to Day 1.For the baricitinib component; subjects will receive either active product or placebo as follows:- Baricitinib will be administered as a 4 mg orally (po) (two 2mg tablets) or crushed for NG tube; daily for the duration of the hospitalization up to a 14-day total course.- A placebo will be given as two tablets po or crushed for NG tube; daily for the duration of the hospitalization up to a 14-day total course.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]